% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

  • hwmccusker hwmccusker Jul 9, 2013 9:25 AM Flag

    All I smell is a pre-clinical rat model and further executive awards after all these months

    The Bottom Line: Is that the best ATHX can do since the Q1/13 earnings were announced. Who cares – it is still too … early to propose this data as relevant! But, the key words were … is working in collaboration with Pfizer (PFE) to complete an ongoing P2 clinical trial in Inflammatory Bowel Disease.

    Genzyme (Sanofi) did the same work … 10 years ago … with hearts and islet cells. Works beautifully in mice, however … Seriously … old news! But, management did … accelerate vesting of awards in the event of involuntary termination of a participant’s employment without cause, and to clarify that restricted stock units may vest over the restriction period. And, on 6/20/13 … entered into incentive agreements with each of its named executive officers establishing an incentive program , which provided the officers financial participation in the event of certain merger or acquisition or asset sale transactions. One-time grants of restricted stock units (RSUs) in the following amounts were granted to the named executive officers for their past service and performance, and in exchange for the termination of their incentive agreements:
    695,040 for Dr. Van Bokkelen; 570,551 for Dr. Harrington; 573,640 for Mr. Lehmann; 491,162 for Dr. Deans; and 369,607 for Ms. Campbell. The RSUs will vest ratably and quarterly over a three-year term. In addition, the named executive officers were granted routine, annual stock-based awards in 6/13.

    ATHX closed at $1.65 and has progressively degraded since 4/30/13 and still NO further partners and an increasing burn rate. I would hide on a Caribbean Island!

    Sentiment: Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.96-0.09(-4.39%)3:42 PMEDT